[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Our Lady of the Lake Hospital\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":73},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,44],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":24,"conditions":25,"keywords":28,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":43},"100566767","utilizing-long-read-sequencing-to-investigate-the-egfr-landscape-of-egfr-positive-lung-cancer-patients-100566767",false,"NCT06659458","Utilizing Long-read Sequencing to Investigate the EGFR Landscape of EGFR Positive Lung Cancer Patients","EGFR Lung Canc","Inclusion Criteria:\n\n* 18-100 years old\n* Biologically born female\n* Diagnosed with EGFR positive lung cancer (Arm 1-Cancer group)\n* No cancer diagnosis (Arm 2-health control)\n\nExclusion Criteria:\n\n* less than 18 years of age\n* Biologically born male\n* Incarcerated at the time of participation",true,"FEMALE","18 Years","100 Years",{"count":21,"type":22},20,"ESTIMATED","OBSERVATIONAL","EGFR gene mutations are some of the most commonly occurring mutations in non-small cell lung cancer. Investigators have developed a DNA instability model that estimates a risk score to assess the likelihood of an individual acquiring a cancer-linked mutation. The aim of this study is to collect blood from both those diagnosed with EGFR positive lung cancer and healthy individuals, evaluate their gene sequence surrounding the EGFR landscape and use the cancer positive and healthy sequences to validate the risk assessment model, which may one day be used to provide insight on susceptibility of getting EGFR positive lung cancer or potentially other cancer types.",[26,27],"Lung Cancer - Non Small Cell","EGFR Exon 19 Deletion Mutation",[29,30],"Lung cancer","EGFR gene","RECRUITING","2025-03-17",{"date":34,"type":35},"2025-03-20","ACTUAL",{"date":37,"type":35},"2025-01-01",{"date":39,"type":22},"2025-12-31",{"name":41,"class":42},"Our Lady of the Lake Hospital","OTHER",1,{"id":45,"slug":46,"hasResults":11,"nctId":47,"briefTitle":48,"officialTitle":48,"acronym":4,"eligibilityCriteria":49,"healthyVolunteers":11,"sex":50,"minAge":18,"maxAge":4,"enrollmentInfo":51,"targetDuration":4,"studyType":53,"phases":54,"briefSummary":56,"conditions":57,"keywords":59,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":65,"lastUpdatePostDateStruct":66,"startDateStruct":68,"completionDateStruct":70,"leadSponsor":72,"locationsCount":4},"100580570","exercise-therapy-in-head-and-neck-squamous-cell-carcinoma-hnscc-100580570","NCT06839014","Exercise Therapy in Head and Neck Squamous Cell Carcinoma (HNSCC)","Inclusion Criteria:\n\n* Adult patients (18 years or older)\n* Diagnosed with head and neck squamous cell carcinoma\n* HPV negative\n* Undergoing treatment at OLOL H\\&N Center\n\nExclusion Criteria:\n\n* Any subject less than 18 years of age.\n* Subjects who have HPV positive HNSCC\n* Subjects who have a pacemaker or electronic implant","ALL",{"count":52,"type":22},40,"INTERVENTIONAL",[55],"NA","The goals of this clinical trial are to learn 1. Determine the feasibility of a home-based exercise analog therapy using Transcutaneous Electrical Nerve Stimulation (TENS), 2. Determine the effects of exercise analog therapy on muscle mass, strength, and clinical outcomes, and 3. Determine the effects of exercise analog therapy on immune phenotype and inflammation response in patients undergoing radiation for head and neck squamous cell carcinoma (HNSCC).\n\nThe main question it aims to answer are:\n\nDoes an exercise regimen using an analog TENS unit during the course of cancer treatment for those with HNSCC improve muscle mass, strength, clinical outcomes and immune response compared to those that do not perform the exercise regimen during their cancer treatment?\n\nResearchers will compare outcomes of patients undergoing cancer treatment + TENS unit exercise to those being treated for their cancer with no exercise TENS unit.\n\nIn the exercise arm, subjects will use the TENS unit for 30 minutes of exercise a day, 3 times a week for the extent of their cancer treatments.\n\nWeekly check-ins by phone or less frequently at scheduled in person visits.\n\nParticipants will keep a log of their exercise sessions to make sure that the exercise occurs 3 times a week for 30 minutes each and note any reasons why a session may have been missed or time shortened.\n\nBoth arms will have a blood draw at the beginning of their cancer treatment and approximately 4 weeks after the last cancer treatment (\\~40mL). These samples will be tested for molecules that signal a higher or lower immune response with the addition of the exercise in one group compared to the cancer therapy only group.",[58],"Head and Neck Squamous Cell Carcinoma HNSCC",[60,61,62,63],"Exercise Therapy","TENS Unit Therapy","Exercise and Cancer","Exercise and Immune Response","NOT_YET_RECRUITING","2025-02-21",{"date":67,"type":35},"2025-02-25",{"date":69,"type":22},"2025-04-01",{"date":71,"type":22},"2026-12-31",{"name":41,"class":42},""]